Metastatic Colorectal Cancer. Real-World Data Analysis.

The Treatment Choices, Duration and Outcomes in Patients With Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04757311

Acronym

RWD-mCRC-001

Enrollment

1750

Registered

2021-02-17

Start date

2020-08-01

Completion date

2021-10-01

Last updated

2021-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Cancer

Brief summary

The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis

Detailed description

In this study, with the given rationale is to reveal treatment approaches, survival data, side effect profile and their management in our country in RAS WT mCRC patients by means of the real-world data collection.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

1. Patients who have been histologically diagnosed with mCRC 2. Patients over the age of 18 3. Patients receiving at least a cycle systemic treatment for metastatic disease 4. RAS wild type patients 5. Patients who has demographic, histopathological and clinical information

Exclusion criteria

1. Patients diagnosed as mCRC but only referred to BSC 2. Patients with RAS mutation 3. Patients who were included in any clinical trial except standard treatments during their treatment

Design outcomes

Primary

Measure	Time frame	Description
Percentage of use anti-EGFR agents	throughout of treatment, 3 years	The anti-EGFR agent selection
Progression Free Survival (PFS)	3 years treatment	PFS three years after initiation of treatment with anti-EGFR agents

Secondary

Measure	Time frame	Description
Advers events	throughout of treatment, 3 years	Advers event of anti EGFR is defined as any untoward or unfavourable medical occurrence, including any abnormal sign, symptom, or disease, temporally associated with the patient's participation. The CTCAE v.4.0 will use in this research.

Other

Measure	Time frame	Description
Percentage of use biologics in right side tumors.	throughout of treatment, 3 years	Treatment selection in right side tumors.

Countries

Turkey (Türkiye)

Outcome results